Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2D6</i> and <i>CYP2C19</i> Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
-
- JK Hicks
- Department of Pharmacy Cleveland Clinic, Cleveland, Ohio, USA; Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA; and Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Cleveland Ohio USA
-
- JR Bishop
- University of Minnesota College of Pharmacy, Department of Experimental and Clinical Pharmacology Minneapolis Minnesota USA
-
- K Sangkuhl
- Department of Genetics Stanford University Stanford California USA
-
- DJ Müller
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto Toronto Ontario Canada
-
- Y Ji
- Department of Laboratory Medicine and Pathology Division of Laboratory Genetics Mayo Clinic Rochester Minnesota USA
-
- SG Leckband
- Veterans Affairs San Diego Healthcare System, Mental Health Care Line, University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences and Department of Psychiatry San Diego California USA
-
- JS Leeder
- Division of Clinical Pharmacology Toxicology & Innovative Therapeutics, Children's Mercy Hospital, Kansas City, Missouri and Department of Pediatrics, University of Missouri‐Kansas City Kansas City Missouri USA
-
- RL Graham
- Philadelphia Veterans Affairs Medical Center Philadelphia Pennsylvania USA
-
- DL Chiulli
- Veterans Affairs Palo Alto Health Care System, San Jose Division San Jose California USA
-
- A LLerena
- CICAB Clinical Research Center Extremadura University Hospital and Medical School Badajoz Spain
-
- TC Skaar
- Division of Clinical Pharmacology Department of Medicine Indiana University School of Medicine Indianapolis Indiana USA
-
- SA Scott
- Department of Genetics and Genomic Sciences Icahn School of Medicine at Mount Sinai New York New York USA
-
- JC Stingl
- Federal Institute of Drugs and Medical Devices Bonn Germany
-
- TE Klein
- Department of Genetics Stanford University Stanford California USA
-
- KE Caudle
- Department of Pharmaceutical Sciences St. Jude Children's Research Hospital Memphis Tennessee USA
-
- A Gaedigk
- Division of Clinical Pharmacology Toxicology & Innovative Therapeutics, Children's Mercy Hospital, Kansas City, Missouri and Department of Pediatrics, University of Missouri‐Kansas City Kansas City Missouri USA
説明
<jats:p>Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. <jats:italic>CYP2D6</jats:italic> and <jats:italic>CYP2C19</jats:italic> polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on <jats:italic>CYP2D6</jats:italic> and/or <jats:italic>CYP2C19</jats:italic> genotype (updates at <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.pharmgkb.org">www.pharmgkb.org</jats:ext-link>).</jats:p>
収録刊行物
-
- Clinical Pharmacology & Therapeutics
-
Clinical Pharmacology & Therapeutics 98 (2), 127-134, 2015-06-29
Wiley
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1364233269188050048
-
- DOI
- 10.1002/cpt.147
-
- ISSN
- 15326535
- 00099236
-
- データソース種別
-
- Crossref